LeadIQ logo
Learn more at LeadIQ.com
Entero Therapeutics (Nasdaq: ENTO) logo

Entero Therapeutics (Nasdaq: ENTO) Employee Directory

Pharmaceutical ManufacturingFlorida, United States2-10 Employees

Entero Therapeutics is a late-stage biopharmaceutical company based in Boca Raton, Florida, with clinical operations in Hayward, California. It develops targeted, non-systemic therapies for gastrointestinal diseases, pursuing unmet GI health needs through a portfolio that includes latiglutenase for celiac disease, which is Phase 3 ready, capeserod for gastroparesis, and adrulipase for exocrine pancreatic insufficiency.

The company builds its development pipeline around two proprietary technologies, niclosamide and adrulipase, with several clinical programs and forthcoming formulations. In October 2025, Entero Therapeutics acquired GRID AI Corp, signaling a strategic move into AI and data-center applications.

Find Entero Therapeutics (Nasdaq: ENTO) employees' phone numbers or email addresses

Entero Therapeutics (Nasdaq: ENTO) Global Highlights

Location
Employees

North America
8

Minus sign iconPlus sign icon
  • United States Of America
    7
  • Canada
    1

Europe
1

Minus sign iconPlus sign icon
  • France
    1

Entero Therapeutics (Nasdaq: ENTO)'s Leadership

  • Chief Financial Officer at Entero Therapeutics (Nasdaq: ENTO)
    A. S.
    Chief Financial Officer
    Mobile Phone
  • Directeur R&D Pharma at Entero Therapeutics (Nasdaq: ENTO)
    Y. L.
    Directeur R&D Pharma
    Mobile Phone

Entero Therapeutics (Nasdaq: ENTO) Employee Metrics

100%
50%
0%
2026
2025
  • Business
  • Entrepreneurship
  • Biotechnology
  • Human Resources
  • Other
  • Quality Assurance

Contact profiles from Entero Therapeutics (Nasdaq: ENTO)

Name
Title
Contact
Location
Last Update
  • Chief Financial Officer at Entero Therapeutics (Nasdaq: ENTO)
    A. S.
    Chief Financial Officer
    Mobile Phone
    Canada
    Oct 28, 2025
  • Directeur R&D Pharma at Entero Therapeutics (Nasdaq: ENTO)
    Y. L.
    Directeur R&D Pharma
    Mobile Phone
    France, Provence-Alpes-Cote D'Azur
    Feb 26, 2024

Frequently Asked Questions

What is Entero Therapeutics (Nasdaq: ENTO) known for?

Minus sign iconPlus sign iconEntero Therapeutics (Nasdaq: ENTO) was founded in 2014 and operates in the Pharmaceutical Manufacturing industry. You can contact Entero Therapeutics (Nasdaq: ENTO)'s main corporate office by phone at
+1-646-699-****
. Explore Entero Therapeutics (Nasdaq: ENTO)'s company overview page for more information.

What is Entero Therapeutics (Nasdaq: ENTO)'s most common email format?

Minus sign iconPlus sign iconEntero Therapeutics (Nasdaq: ENTO) employees' email format typically follows the pattern of FLast@azurrx.com. Trying to find reliable and up-to-date employee contact data? Find more Entero Therapeutics (Nasdaq: ENTO) email formats with LeadIQ.

How many employees does Entero Therapeutics (Nasdaq: ENTO) have currently?

Minus sign iconPlus sign iconEntero Therapeutics (Nasdaq: ENTO) has approximately 5 employees as of August 2026. These team members are located across 2 continents, including North America and Europe.

Who are Entero Therapeutics (Nasdaq: ENTO)'s key employees and leadership?

Minus sign iconPlus sign icon

As of August 2026, Entero Therapeutics (Nasdaq: ENTO)'s key employees include:

  • Chief Financial Officer: A. S.
  • Directeur R&D Pharma: Y. L.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

  • B2B data verified in real-time
  • Sync data to your CRM, & add it to an outreach sequence in one click
  • Integrations with your tech stack for optimal efficiency
  • A patented AI cold email generator
  • Account & contact-level job change tracking

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.